Lv2
140 积分 2024-09-19 加入
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?
2个月前
已完结
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
2个月前
已完结
Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology
2个月前
已完结
Image-guided adaptive radiotherapy for nasopharyngeal carcinoma
2个月前
已关闭
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma
2个月前
已完结
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
4个月前
已完结
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
4个月前
已完结
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
4个月前
已完结
The climb toward intracranial efficacy: Zorifertinib in EGFR-mutant NSCLC with CNS metastases in the EVEREST trial
7个月前
已完结
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
7个月前
已完结
皖公网安备34019202002308
